SOTIO's SOT106 ADC wins FDA Fast Track for soft tissue sarcoma
SOTIO Biotech has received Fast Track Designation from the US Food and Drug Administration for SOT106, its investigational antibody-drug conjugate targeting the LRRC15 protein, for the treatment of soft tissue sarcoma. The Prague- and Boston-headquartered company, backed by Czech conglomerate PPF Group, expects to begin a first-in-human clinical trial before the end of 2026.
Fast Track Designation is awarded by the FDA to therapies intended to address serious conditions with unmet medical need. It enables more frequent agency interactions during development and may open the path to rolling review and Priority Review, provided the relevant criteria are met at the time of filing.
The science and the target
SOT106 is designed to bind LRRC15, a protein broadly expressed across multiple soft tissue sarcoma subtypes. The company describes the target as clinically validated, though it has not released preclinical efficacy data or payload or linker specifications in the materials accompanying this announcement. LRRC15 has attracted interest as an ADC target because of its restricted expression in normal adult tissue relative to its elevation in several solid tumour types, a profile that theoretically widens the therapeutic window.
Vivi Boura, chief medical officer at SOTIO, said soft tissue sarcomas represent "a major unmet medical need, where decades of therapeutic progress have yet to translate into meaningful improvements for patients with advanced or recurrent disease." She added that the Fast Track milestone reinforces the programme's potential to address difficult-to-treat sarcoma subtypes. SOT106 also holds FDA Orphan Drug Designation for osteosarcoma, granted in May 2026, further signalling regulatory recognition of need across the sarcoma spectrum.
Market context and competitive landscape
Soft tissue sarcoma is a heterogeneous and historically underfunded indication. Doxorubicin remains a standard first-line option despite having been in use for decades, and response rates in later lines are modest. The designation reflects genuine clinical need rather than commercial volume, which is why sarcoma has drawn growing ADC interest in recent years. Several academic centres and smaller biotechs are exploring ADC approaches in sarcoma subtypes, and the LRRC15 target itself has been investigated by other programmes in sarcoma and breast cancer contexts.
SOTIO is building a focused ADC pipeline alongside SOT106. Its second lead programme, SOT109, targets CDH17 in colorectal cancer and also received Fast Track Designation in July 2026. A third asset, SOT201, is a PD-1-targeting immunocytokine currently in the Phase 1 VICTORIA-01 study in solid tumours. The dual Fast Track momentum across SOT106 and SOT109 in the space of two months is likely to increase visibility for the company among European and US oncology investors as it approaches its first clinical readout.
The key near-term milestone for SOT106 is the initiation of its first-in-human study, after which dose-escalation safety and pharmacokinetic data will be the primary indicators of whether the programme can advance competitively in a sarcoma ADC field that remains early but increasingly crowded.